On June 11, 2026, the 3rd Global MedTech Conference (Global MedTech Conference 2026) was held at the Beijing Zhongguancun Exhibition Center Conference Hall.

As an important component of MedChina (Siyu MedTech)'s annual MedTech conference series, this year's conference attracted over 600 professional guests from hospitals, research institutes, innovative enterprises, investment institutions, and industrial service platforms. Focusing on hot topics including innovative medical device R&D, medical technology transfer, clinical needs, and commercialization implementation, guests shared practical experiences, exchanged industry observations, and jointly explored the development direction of medical technology innovation.

On-site at the conference, the 2026 Global MedTech Innovation Awards were officially unveiled. This year's awards included the Innovative Medical Device Award and the Medical Application Innovation Award. The Innovative Medical Device Award was primarily granted to participating enterprises that had obtained innovative product registration approval from the National Medical Products Administration (NMPA), with a focus on representative enterprises that had achieved a large number of innovative device approvals, systematic innovation layouts, or national firsts and key technological breakthroughs.

Special Note: MedTech organizes awards twice annually. The judging panel can only select from registered applicants. Please follow the November announcement and actively apply to participate.

The award winners are listed below (in no particular order).

2026 Innovative Medical Device Award

6 Winners

Shanghai United Imaging Healthcare Co., Ltd.

Award Citation:

Shanghai United Imaging Healthcare Co., Ltd. has long adhered to independent R&D of high-end medical imaging equipment, and has formed an innovative product system covering CT, MRI, PET/CT, PET/MR, DSA, and radiotherapy equipment.

In MedChina (Siyu MedTech)'s statistical review of innovative medical devices that have passed the NMPA's Special Review Program for Innovative Medical Devices and received approval over the years, United Imaging Healthcare is one of the enterprises with the largest number of approved innovative medical devices, and is also one of the few domestic medical equipment enterprises that has continuously achieved innovative breakthroughs across multiple high-end imaging tracks. In recent years, the company has successively launched representative innovative products such as the whole-body clinical ultra-high-field 5T MRI, Total-Body PET/CT, photon-counting CT, and dual wide-bore dual-source CT, with multiple achievements achieving China-first or global-first status.

As an important representative enterprise of domestic independent innovation in high-end medical imaging equipment, United Imaging Healthcare has not only achieved technological breakthroughs in individual products, but has also built a systematic innovation capability covering multiple product lines and technology platforms, continuously driving the development of domestic high-end medical equipment to higher levels.

Beijing PINS Medical Co., Ltd.

Award Citation:

Beijing PINS Medical Co., Ltd. has long focused on neural interface product R&D and industrialization, and has formed a relatively complete product portfolio in fields such as deep brain stimulators (DBS), vagus nerve stimulators, sacral nerve stimulators, and spinal cord stimulators.

The company's next-generation DBS G108R received NMPA approval in March 2026. The product achieves upgrades in device volume, charging efficiency, multi-electrode compatibility, and multi-stimulation modes, and reserves closed-loop neuromodulation technology interfaces, providing a foundation for the future development of intelligent neuromodulation therapy. Meanwhile, the closed-loop stimulation clinical study of DBS led by the company has also completed multiple implantations, marking that China's DBS technology has begun entering the new stage of intelligent brain-computer interfaces.

Hunan Antitumor and Health Reconstruction Biotechnology Co., Ltd.

Award Citation:

Hunan Antitumor and Health Reconstruction Biotechnology Co., Ltd. focuses on innovative tumor treatment methods, central nervous system injury repair, and neurorehabilitation treatment technology and product R&D. The company's independently developed ASCLU series tumor treating fields (TTF) therapy device entered the NMPA Special Review Program for Innovative Medical Devices in 2020, and received NMPA approval in 2025.

This product is China's first approved domestic tumor treating fields therapy device for glioblastoma treatment, marking that China has achieved technological self-sufficiency in the field of brain tumor physical therapy, filling the domestic gap in tumor treating fields therapy. The clinical trial was led by Beijing Tiantan Hospital, Capital Medical University, with 11 tertiary Grade-A hospitals nationwide participating jointly, providing important evidence-based support for its clinical application and promoting the standardized development and improved clinical accessibility of tumor treating fields therapy technology domestically.

GenLight MedTech Ltd.

Award Citation:

GenLight MedTech Ltd. focuses on the industrialization of cutting-edge technologies in brain science and neuromedicine, continuously deploying around directions such as brain-computer interfaces, laser energy, and neuromodulation.

The company has built a neurological disease solution covering "precision diagnosis — minimally invasive treatment — long-term regulation." Among them, the S-Deep™ intracranial deep brain electrode and LaserRO™ MRI-monitored semiconductor laser therapy system have received NMPA Class III registration certificates, while the Epilcure™ implantable neurostimulation system is in the registration advancement stage. The synergistic layout of multiple products reflects the enterprise's continuous innovation and transformation capabilities in the field of nervous system disease diagnosis and treatment.

Shenzhen Zhongke Jingcheng Medical Technology Co., Ltd.

Award Citation:

Shenzhen Zhongke Jingcheng Medical Technology Co., Ltd. was incubated and established by the Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, focusing on innovative medical device R&D and technology transfer in the fields of orthopedics, neurosurgery, and stomatology.

The company's core product, "Bogulie® Magnesium-Containing Degradable Polymer Bone Repair Material," received NMPA approval in May 2025. This product innovatively integrates magnesium-containing composite material technology with low-temperature 3D printing additive manufacturing processes, constructing a macro-micro porous three-dimensional biomimetic structure, achieving key technological breakthroughs in the field of bone defect repair, and filling the domestic gap in the clinical application of magnesium-based bone repair materials.

The product combines early mechanical support performance with bone repair promotion capabilities, and can gradually degrade and be absorbed within a 6–9 month cycle, ultimately being replaced by newly formed bone tissue, providing a domestic innovative solution with independent intellectual property rights for bone defect repair.

Chengdu NOVEL MEDICAL Equipment Co., Ltd.

Award Citation:

Chengdu NOVEL MEDICAL Equipment Co., Ltd. has long been deeply engaged in the nuclear medicine molecular imaging field, and is one of the earlier domestic enterprises to achieve independent R&D of nuclear medicine core equipment.

The company's independently developed Insight 4D Quantitative SPECT/CT received NMPA innovative medical device approval, with fully independent intellectual property rights. This product addresses precision diagnosis and treatment needs in nuclear medicine, enhancing imaging quantitative analysis capabilities and equipment comprehensive utilization efficiency, and has currently been deployed at medical institutions such as Peking Union Medical College Hospital. As one of the representative products of domestic high-end nuclear medicine equipment, its launch has further promoted the domesticization process of nuclear medicine imaging equipment.

2026 Medical Application Innovation Award

4 Winners

Qingdao Haier Biomedical Co., Ltd.

Award Citation:

Qingdao Haier Biomedical Co., Ltd. is an important strategic layout of Haier Group's health sector Yingkang Life in the life sciences industry, and was listed on the STAR Market in 2019 (stock code: 688139). In May 2026, the company received certification from Euromonitor International as "No. 1 in Global Life Science Laboratory Equipment Sales among Chinese Independent Brands" and "No. 1 in Overseas Sales of Global Life Science Laboratory Equipment among Chinese Independent Brands" (data period: 2025 global sales of life science laboratory equipment by Chinese independent brands).

The company focuses on the life sciences and medical health fields, providing digital scenario comprehensive solutions around directions such as low-temperature storage, digital intelligent research, smart medication use, and blood technology, driving innovation in life science R&D and medical service scenarios through AI and automation technologies. Products and solutions have been applied in over 160 countries and regions globally, and the company maintains long-term cooperation with nearly 80 international organizations including the World Health Organization (WHO) and UNICEF, representing one of the Chinese life science laboratory equipment brands in international development.

Beijing Tonghe Litai Biotechnology Co., Ltd.

Award Citation:

Beijing Tonghe Litai Biotechnology Co., Ltd. has constructed and operates China's first large-animal testing barrier-level platform primarily using pigs, designated by the Beijing Municipal Science and Technology Commission as the "Medical Device Collaborative Innovation and Common Service Technology Platform."

The company provides full-process services from protocol design, animal testing, pathological analysis, to report output in fields such as cardiovascular, neurosurgery, orthopedic implants, energy ablation, and surgical robots. Since its establishment, it has cumulatively served over 1,300 projects and issued over 900 medical device preclinical animal testing reports. As an important supporting platform in the medical device innovation chain, Tonghe Litai has provided critical support for the R&D verification and registration transformation of numerous innovative products.

SinoVision Technology (Beijing) Co., Ltd.

Award Citation:

SinoVision Technology (Beijing) Co., Ltd. has long focused on CT imaging technology innovation, forming a characteristic product portfolio around large-bore specialized CT.

The company's launched SigmaCT 720 Tianji is China's first dual-foot weight-bearing orthopedic joint CT, developed to address the need for true weight-bearing state 3D high-definition imaging in the diagnosis and treatment of foot and ankle and orthopedic diseases, and received market approval in May 2026. The product enables specialized examinations of multiple body parts including dual-foot, dual-knee, and wrist in both weight-bearing and non-weight-bearing positions, providing more precise imaging support for foot and ankle disease diagnosis, preoperative planning, and postoperative evaluation, demonstrating the direction of imaging equipment innovation oriented toward specialized clinical needs.

Ambulanc (Shenzhen) Tech. Co., Ltd.

Award Citation:

Ambulanc (Shenzhen) Tech. Co., Ltd. has long been engaged in emergency and critical care medical device R&D and manufacturing, and is a leading enterprise in China's emergency and critical care equipment field, a national-level specialized and innovative "Little Giant" key enterprise.

The company covers innovative products such as mechanical cardiopulmonary resuscitation, ventilators, thoracic electrical impedance tomography, and electrical defibrillation. Its innovative cardiopulmonary resuscitation defibrillator complies with the latest international cardiopulmonary resuscitation guidelines, seamlessly integrating mechanical compression, electrical defibrillation, and high-quality blood oxygen/end-tidal carbon dioxide monitoring to improve rescue efficiency. Through innovative technology, the company leads industry development, with products exported to domestic and overseas markets, serving over 100 countries and regions globally.

Conclusion

From tumor treating fields therapy and magnesium-containing degradable bone repair materials, to nuclear medicine imaging, neuromodulation, and brain science innovative therapies, and further to specialized imaging equipment, emergency life support systems, and preclinical research platforms, this year's award-winning enterprises cover multiple key links in medical technology innovation.

Among them, the Innovative Medical Device Award showcases the new progress achieved in China's innovative medical device field in recent years. The core products of multiple award-winning enterprises have received market approval through the NMPA Special Review Program for Innovative Medical Devices, achieving key technological breakthroughs in fields such as high-end imaging, neuromodulation, bone repair, and tumor treatment, reflecting the continuously strengthening independent innovation capabilities of China's medical device industry.

In the future, MedChina (Siyu MedTech) will continue to focus on outstanding enterprises and teams with clinical value, innovation capabilities, and industrialization potential in the medical technology field, jointly witnessing China's medical technology innovation continuously reaching new heights.

June 11, 2026